Stockscreener 앱 받기
31.62
4.67%
1.41
시간 외 거래:
31.82
0.20
+0.63%
Neurogene Inc 주식(NGNE)의 최신 뉴스
Can a trend reversal in Neurogene Inc. lead to recoveryWeekly Stock Recap & Growth Focused Entry Reports - newser.com
Price action breakdown for Neurogene Inc.Trade Volume Report & Capital Efficiency Focused Strategies - newser.com
How to track smart money flows in Neurogene Inc.July 2025 Big Picture & High Return Stock Watch Alerts - newser.com
Why Neurogene Inc. stock remains a top recommendationM&A Rumor & AI Enhanced Market Trend Forecasts - newser.com
Why Neurogene Inc. stock is popular among millennials2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
Does Neurogene Inc. qualify in momentum factor screeningProduct Launch & Reliable Price Action Trade Plans - newser.com
Neurogene’s (NGNE) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Neurogene (NASDAQ:NGNE) - MarketBeat
Neurogene (NASDAQ:NGNE) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
How Neurogene Inc. (UU8) stock responds to job market shiftsJuly 2025 Sector Moves & High Win Rate Trade Tips - newser.com
HC Wainwright & Co. Reiterates Neurogene (NGNE) Buy Recommendation - Nasdaq
Neurogene Reaches Accord With FDA on Plan for Registrational Trial for Rett Syndrome Gene Therapy NGN-401 - CGTLive®
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Fourth Quarter of 2025 - MarketScreener
Neurogene to begin Rett syndrome gene therapy registrational trial in Q4 - Investing.com
Real time pattern detection on Neurogene Inc. stockQuarterly Trade Summary & Advanced Swing Trade Entry Alerts - newser.com
Neurogene Completes FDA Talks for Rett Syndrome Trial - TipRanks
Neurogene : Poster ESGCT2025 RoA Final Print - MarketScreener
23 developmental milestones — Neurogene to start Embolden dosing in Q4 2025 after FDA talks and ICV data - Stock Titan
What recovery options are there for Neurogene Inc.2025 Top Gainers & Low Risk Entry Point Guides - newser.com
Forecasting Neurogene Inc. price range with options dataTrade Exit Summary & Real-Time Stock Entry Alerts - newser.com
What drives Neurogene Inc UU8 stock priceBollinger Bands Signals & Free Explosive Wealth Accumulation - earlytimes.in
Oct 14, 7:00 a.m. ET: Neurogene to Present at H.C. Wainwright Virtual Conference — webcast available - Stock Titan
What analysts say about Neurogene Inc stockInflation Impact on Stocks & Big Data Market Reports - earlytimes.in
Short interest data insights for Neurogene Inc.July 2025 Highlights & Entry Point Confirmation Signals - newser.com
Is Neurogene Inc a good long term investmentWeekly Market Snapshot & Free Rapid Profit Acceleration - earlytimes.in
Neurogene Insiders Placed Bullish Bets Worth US$1.46m - simplywall.st
Strategies to average down on Neurogene Inc.Portfolio Performance Summary & Free Fast Gain Swing Trade Alerts - newser.com
Long term hold vs stop loss in Neurogene Inc.2025 Year in Review & Momentum Based Trading Ideas - newser.com
Neurogene announces inducement grants under Nasdaq Listing Rule - MarketScreener
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
We're Not Very Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Rate - 富途牛牛
Developing predictive dashboards with Neurogene Inc. dataQuarterly Market Review & Weekly Return Optimization Plans - newser.com
Does Neurogene Inc. stock trade at a discount to peersJuly 2025 Patterns & Free Community Consensus Stock Picks - newser.com
Is Neurogene Inc. trending in predictive chart modelsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright - TipRanks
Batten Disease Pipeline 2025: Innovative Clinical Developments by 10+ Global Leaders – DelveInsight | Featuring Polaryx Therapeutics, Neurogene, Theranexus, M6P Therapeutics, Regenxbio - The Globe and Mail
1.11%
자본화:
|
볼륨(24시간):